Zhiyang Zhao Alliance Pharma Malvern, PA USA Biography
Biography of Zhiyang Zhao
Zhiyang Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Tech, Blacksburg, Virginia, USA. Dr. Zhao’s biopharmaceutical/pharmaceutical work experience encompasses over 25 years of research in metabolic and pharmacokinetic properties of compounds for drug discovery and development at Pfizer, GlaxoSmithKline and Amgen. Currently, Dr. Zhao serve as Chief Scientific Officer (CSO) at Alliance Pharma, Inc. and appointed as an adjunct professor at the School of Pharmacy, the University of North Carolina at Chapel Hill. Dr. Zhao has published over 50 peer reviewed original research papers and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.
Suresh K Balani Takeda Pharmaceuticals International Company Cambridge, MA USA
Michael Sinz Bristol Myers Squibb Wallingford, CT USA Biography
Biography of Michael Sinz
Michael W. Sinz, Ph.D. is Director of Metabolism and Pharmacokinetics at Bristol Myers Squibb where he manages ADME lead optimization in drug discovery. Dr. Sinz previously held the position of Section Director-Pharmacokinetics and Drug Metabolism for Parke-Davis/Pfizer. He received B.S. degrees in Chemistry (ACS) and Biology from the University of Wisconsin-Eau Claire and a Ph.D. in Pharmacognosy/Medicinal Chemistry from the University of Minnesota (2001). He is editor in chief of Current Drug Metabolism and associate editor of Drug Metabolism Letters. Dr. Sinz’s resume includes an extensive number of peer reviewed publications, book chapters, and external presentations both locally and internationally.
Nico P.E. Vermeulen Vrije Universiteit Amsterdam Amsterdam The Netherlands Biography
Biography of Nico P.E. Vermeulen
Prof. Nico P.E. Vermeulen received a doctorate degree in Chemistry (1975, University of Nijmegen, NL) and a PhD degree in Pharmacology (1980, University of Leiden, NL). He was appointed full professor in Molecular Toxicology at VU University Amsterdam (1985). Currently, he is also Director of AIMMS (Amsterdam Institute for Molecules, Medicines and Systems, at VU University). He is author of > 405 peer reviewed publications and was listed at the ISI HighlyScited.com list (e.g. 2001 and 2014). He is interested in the roles molecular and computational toxicology and drug metabolism can play in drug discovery, development and safety assessment.
Editorial Board Members
U.A. Argikar Novartis Institutes for BioMedical Research, Inc. Cambridge, MA USA Biography
Biography of U.A. Argikar
Upendra A. Argikar is a Senior Research Investigator at Novartis Institutes for Biomedical Research, Inc. in Cambridge, Massachusetts, USA. He received a Ph.D. in Medicinal Chemistry from University of Minnesota, USA. He has 15+ years of research experience in drug metabolism and pharmacokinetics. At Novartis he has been an active member of projects spanning many disease areas. Currently, he focuses on metabolite identification and structure elucidation of new chemical entities and clinical candidates. Upendra has continued to be interested in conjugative metabolism by uridine diphospho-glucuronosyl transferases, a topic on which he has co-authored research articles, reviews, and book chapters.
Y. Daali Geneva University Hospitals Geneva Switzerland Biography
Biography of Y. Daali
Since 2002, I’m the Head of the Research Laboratory of the Clinical Pharmacology and Toxicology Service at Geneva University Hospitals. I completed my doctorate in Pharmaceutical Sciences at the School of Pharmacy of Geneva University in 2001. I joined the Clinical Pharmacology Service at Geneva University Hospitals in 2002. I’m also a senior lecturer at School of Pharmacy and at Medical school of Geneva University. My research activity is related to personalized medicine related to drug metabolism, pharmacokinetics and PBPK. I also developed several in vitro models for drugs metabolism and transport characterization and drug-drug interaction studies.
J.S. Daniels Vanderbilt University Medical Center Nashville, TN USA
H. Glatt German Institute of Human Nutrition (DIfE) Nuthetal Germany
M.M. He Lilly Research Laboratories Indianapolis, IN USA Biography
Biography of M.M. He
Dr. He is currently a Research Advisor in Drug Disposition at Lilly Research Laboratories, with 20+ year’s pharmaceutical industry experience in discovery and development of drug candidates across different therapeutic areas. She received her Ph.D. degree in Medicinal Chemistry (Drug Metabolism) from University of Washington. Dr. He’s research interest includes drug metabolism and disposition, in vivo/vitro/in silico ADME, DMPK differences in disease models and ethnic populations. Her current research focuses on IVIVE and ADME translation including species scaling and extrapolations, mechanistic PBPK modeling and predictions of human clearance and drug-drug interactions.
W.G. Humphreys Bristol-Myers Squibb Princeton, NJ USA
M. Kajbaf GlaxoSmithKline S.p.A. Fleming, Verona Italy Biography
Biography of M. Kajbaf
Dr Mahmud Kajbaf holds a Ph.D. from the University of London, King’s College, Biopharmacy Department in the area of drug metabolism and MSc from Aston University, Birmingham.
Currently Dr Kajbaf is Senior Scientist at Aptuit. He has received several awards and honors, such as: Aptuit CEO Excellence Award, GlaxoSmithKline the psychiatry CEDD Leadership Team Award. He is also on the editorial board for several journals. He has published over 33 research articles related to drug metabolism, in vivo-in vitro correlation, drug-drug interaction, HPLC, NMR and mass spectrometry.
E. Kantharaj R & D Technical, D3, A*STAR Singapore
R.S. King University of Rhode Island Kingston, RI USA Biography
Biography of R.S. King
Dr. King earned a doctorate (Ph.D.) in Medicinal Chemistry from the University of Iowa, Iowa City. Her postdoctoral fellowship was in molecular toxicology at the National Center for Toxicological Research, followed immediately by earning a faculty position at the University of Rhode Island, College of Pharmacy in 1999. Dr. King is currently Professor of Biomedical and Pharmaceutical Sciences. Dr. King's research spans protein structural biology, receptor-based drug design, all aspects of drug-xenobiotic-hormone metabolism, and liver enzymology.
A.P. Li In Vitro ADMET Laboratories Columbia, MD United States Biography
Biography of A.P. Li
Dr. Li (Ph. D., Biomedical Sciences, University of Tennessee) is President and CEO of In Vitro ADMET Laboratories Inc., Columbia, MD. He was previously Senior Fellow, Monsanto Company; CSO, In Vitro Technologies; Research Professor, St. Louis University Medical School, and CEO, Phase 1 Molecular Toxicology. His research is focused on the development and application of human-based in vitro experimental models in the accurate assessment of human drug properties including metabolic fate, drug-drug interactions and drug toxicity. Dr. Li has published over 170 research articles, book chapters, and reviews, and co-edited 5 books. He holds multiple U.S and international patents.
K. Liu Dalian Medical University Dalian China Biography
Biography of K. Liu
Kexin Liu received his B.S. degree in Clinical Medicine and M.S. degree in Pharmacology from Dalian medical University in China and Ph. D. degree in Pharmacy in The University of Tokyo (Laboratory of Yuichi Sugiyama, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences) in Japan. The focus of his research is on the molecular pharmacokinetics of transport in liver, intestine, kidney as well as transporter-mediated DDI and MDR. Prof. Kexin Liu is a co-author of more than 250 publications in international journals. He serves as a vice president of CSSX from 2005 and a dean in College of Pharmacy in Dalian Medical University from 2004.2-2015.1.
B.L. Lum Genentech Research and Early Development South San Francisco, CA USA Biography
Biography of B.L. Lum
Dr. Lum is a Principal Scientist at Genentech, Inc., where he has been employed for approximately 13 years in the Department of Clinical Pharmacology. He has served a leading role in the development and marketing approvals for a variety of small molecule and protein therapeutics, such as trastuzumab (Herceptin IV/SC), erlotinib (Tarceva), bevacizumab (Avastin), pertuzumab (Perjeta) vismodegib (Erivedge), and ado-trastuzumab (Kadcyla). Prior to moving to Genentech, Dr. Lum was a tenured Professor of Pharmacy at the University of the Pacific and Associate Director of the Clinical Trials Office in the Stanford University Medical Center. He has published over 100 manuscripts.
S. Mandlekar Bristol-Myers Squibb India Pvt. Ltd. Bangalore India Biography
Biography of S. Mandlekar
Sandhya Mandlekar is the Director of Pharmaceutical Candidate Optimization Department at the Biocon Bristol-Myers Squibb R&D Center (BBRC) in Bangalore, India. She also worked in the non-clinical DMPK field at BMS, NJ and DuPont Pharmaceuticals, DE for several years. She received her Ph.D. degree in Pharmaceutical Sciences from the College of Pharmacy at the University of Illinois, Chicago. Sandhya was responsible for setting up and equipping the laboratories, recruitment and staffing, and directing a group of scientists in drug metabolism, pharmacokinetics, bioanalytical sciences, and toxicology at the BBRC. She has published over 50 peer-reviewed articles and also serves as a reviewer for reputed journals.
M. Markuszewski Medical University of Gdańsk Gdańsk Poland Biography
Biography of M. Markuszewski
Prof. Michal J. Markuszewski studied pharmacy at the Medical University of Gdansk, Poland. In 2000, he earned his PhD in pharmaceutical sciences under prof. Roman Kaliszan supervision and next for two years joined, as a post-doc, group of prof. Shigeru Terabe at Himeji Institute of Technology (currently Hyogo University). Currently he is a Head of the Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdansk. His scientific interest comprises the metabolomics, cancer biomarkers, pharmacokinetics, application of separation techniques for pharmaceutical analysis (LC-MS, CE-MS) and bioinformatics. He was invited lecturer during international symposia and conferences (more than 20).
M. Moghaddam Celgene Corporation San Diego, CA USA Biography
Biography of M. Moghaddam
Dr. Mehran F. Moghaddam obtained his PhD in medicinal chemistry at Oregon State University-School of Pharmacy and investigated novel lipid metabolism at University of California-Davis as a postdoctoral researcher. He also completed an executive MBA at University of Southern California. He started his industrial career by joining DuPont in 1995. Subsequently, he worked in Pfizer and Celgene. He is currently the head of Discovery Drug Metabolism and Pharmacokinetics (DMPK) at Celgene, a global biopharmaceutical company with marketed blockbuster drugs in oncology and anti-inflammatory spaces.
Dr. Moghaddam has been a co-inventor on more than 5 patents. He has authored/co-authored more than 50 manuscripts on a variety of subject matters. He is on the editorial board of Drug Metabolism Letters and DARU. Additionally, he is a section editor for Current Medicinal Chemistry.
A.F. Nassar Brandies University Waltham, MA USA
C. O. Onyeji Obafemi Awolowo University Ile-Ife Nigeria Biography
Biography of C. O. Onyeji
Promoted to Professorship position in 1999 at Obafemi Awolowo University, Ile-
Ife, Nigeria, Prof Cyprian Onyeji occupied various posts including Deanship of his
Faculty. Outside the University, he served as Governing Board member of
different establishments. He was appointed Vice-Chancellor of Enugu State
University of Science and Technology, and completed the tenure in 2015. He has
made excellent contributions to the advancement of Science through his studies
with focus on pharmacokinetic, metabolism and pharmacodynamic evaluations of
anti-infective drugs, with the overall objective of generating information relevant
for optimization of therapeutic utility of the drugs.
K.B. Park University of Liverpool Liverpool UK Biography
Biography of K.B. Park
Professor Kevin Park is currently Professor of Pharmacology and Head of the Institute of Translational Medicine at the University of Liverpool. Professor Park is a Fellow of the Royal College of Physicians, a Fellow of the Academy of Medical Sciences and also a Commissioner on Human Medicines. The over-riding theme of his work is bringing “molecule–to-man” and back again, to enable the prediction of adverse drug reactions based on the chemical structure of the drug and the identification of susceptible individuals. This work has been expanded by using pharmacogenomics and toxicogenomics to link findings in patients to the chemical structure of the drug. The group are now in a position to provide solutions to adverse drug reactions through research in two areas: 1) improved drug design and 2) the delivery of individualised medicines.
C. Prakash CP Pharma Consulting Principal, Drug Metabolism and Pharmacokinetics MA USA
S. Pusalkar Takeda Pharmaceuticals Inc. Cambridge, MA USA Biography
Biography of S. Pusalkar
Dr. Pusalkar obtained a doctorate degree (Ph.D.) in Medicinal Chemistry from Massachusetts College of Pharmacy and Health Sciences, Boston, MA. Dr. Pusalkar has more than 15 years of experience in drug metabolism and pharmacokinetics field and currently leads the Enzymology Group at Takeda Pharmaceuticals, Intl’ Co. in Cambridge, MA.
M.K. Ross Mississippi State University Starkville, MS USA Biography
Biography of M.K. Ross
My research program seeks to understand how cells respond and adapt to stressful stimuli at the molecular and biochemical level. A primary focus has been on the carboxylesterase enzymes because of their important roles in xenobiotic and endobiotic metabolism, including their ability to catabolize drugs, toxicants, and lipids. Our research includes studies on carboxylesterase enzymology and gene regulation; how carboxylesterase activity influences macrophage cell physiology and phenotype; and inter-individual variations in its activity within human populations. Our group is also interested in macrophage reverse cholesterol transport, and investigating how lipid metabolism and inflammation intersect in these immune cells.
J.F. Rusling University of Connecticut Storrs, CT USA Biography
Biography of J.F. Rusling
James F. Rusling was awarded the B.Sc. in Chemistry from Drexel University in 1969, and Ph. D. from Clarkson University in 1979. He is Professor of Chemistry at University of Connecticut, Professor of Surgery and member of the Neag Cancer Center at University of Connecticut Health Center, and adjunct Professor of Chemistry at National Univ. of Ireland. Galway. Current research includes new cancer diagnostics via detection of biomarker proteins, low-cost 3D printed immunoarrays for point-of-care diagnostics, electrochemical and mass spectrometric arrays for toxicity screening, tumor suppressor gene damage, and fundamental bioelectrochemistry. He has authored more than 380 research papers and several books, and is a musician interested in Irish and American folk styles.
M. Soars Bristol-Myers Squibb Wallingford, CT USA Biography
Biography of M. Soars
Dr Soars is a Senior Principal Scientist in the Metabolism and Pharmacokinetics department at Bristol-Myers Squibb in Wallingford CT. He received his Bachelors in biochemistry from the University of Warwick in 1998 and a Phd from the University of Dundee in 2002. From 2002-2003, he completed a postdoctoral fellowship at Eli Lilly where he worked on drug glucuronidation under the supervision of Steve Wrighton. He then moved to AstraZeneca where he worked for 8 years developing and implementing both drug metabolism assays and more recently transporter methodology. Since 2011 Dr. Soars has worked at Bristol –Myers Squibb where he helped develop the transporter strategy in Drug Discovery. Research interests include the prediction of pharmacokinetics and drug-drug interactions for new chemical entities and also the application of drug transporter methodology in early Drug Discovery. Dr Soars has published more than 30 scientific publications and is on the Editorial advisory board for a number of publications including Xenobiotica, Current Drug Metabolism and Drug Metabolism letters.
M. Ulgen Acibadem University Istanbul Turkey Biography
Biography of M. Ulgen
Prof. Dr. Mert Ulgen graduated from Marmara University, Faculty of Pharmacy, Istanbul, Turkey in 1981. He finished his MSc degree at the same department and in 1992, he obtained a PhD degree from University of London, King's College, Biopharmacy Department in the area of Drug Metabolism. He returned to Turkey and became an associated Professor in 1993 and a full professor in 1999 at the same department in the area of Pharmaceutical Chemistry. He has got a number of papers on drug synthesis and in vitro hepatic microsomal metabolism of xenobiotics. He directed a number of MSc and PhD thesis. He retired from Marmara University in June 2009 and he became a full time Professor at Acıbadem University, Vocational School of Health Services in the same year. He has a number of administrative duties. He is also a full time chemistry lecturer. He was Director of Enstitute of Health Sciences in Acıbadem University one term (2013-2016). He established Faculty of Pharmacy at the same University in early 2016 and he is currently dean of Pharmacy. He is also head of "Management in Drug Industry" MSc Program.
R.J. Weaver Institut de Recherches Internationales Servier Suresnes Cedex France Biography
Biography of R.J. Weaver
Dr. Weaver obtained his first degree in Biochemistry & Toxicology (Hons) from the University of Surrey, Guildford, and PhD from the Dept. of Medicine & Therapeutics, University of Aberdeen. Dr. Weaver also holds a Masters of Business Administration (MBA) from the Warwick Business School, Warwick University, UK. Currently Dr Weaver is Associate Scientific Director, Servier Group, France. Affiliations included Fellow of the Royal Society of Chemistry, European Registered Toxicologist and Committee Member of the Preclinical Drug Safety and Biological Discovery Expert Committees.
B. Wen GlaxoSmithKline King of Prussia, PA USA Biography
Biography of B. Wen
Bo Wen, Ph.D. is Research Fellow at GlaxoSmithKline Pharmaceutical Research and
Development. Prior to GSK, Dr. Wen held multiple positions at Hoffmann-La Roche and Bristol-
Myers Squibb. He received his B.Sc. in Pharmaceutical Sciences from China Pharmaceutical
University and Ph.D. in Medicinal Chemistry from the University of Washington. He has authored
over 30 peer-reviewed papers and book chapters in the fields of biotransformation, bioactivation
of xenobiotics, and the molecular mechanisms of drug metabolism and chemical toxicology.
H. Yamazaki Showa Pharma University Tokyo Japan Biography
Biography of H. Yamazaki
Dr. Hiroshi Yamazaki has been Professor of Laboratory of Drug Metabolism and Pharmacokinetics at Showa Pharmaceutical University, Tokyo, Japan since 2005. He received his PhD degree from Osaka University in Japan and was trained at Vanderbilt University, TN, USA in 1994. He was a scientist at Osaka Prefectural Institute of Public Health and an Associate Professor of Kanazawa (1998) and Hokkaido (2001) University. He has authored over 340 publications and has been the recipient of the Japanese Society for the Study of Xenobiotics (JSSX) Award and Fellow. He is a member of several editorial committees and the JSSX President-elect (2016-2017).
Associate Editorial Board Members
M. Gunduz Novartis Institutes for Biomedical Research Cambridge, MA USA Biography
Biography of M. Gunduz
Mithat Gunduz is a Research Investigator at Novartis Institutes for Biomedical Research, Inc. in Cambridge, Massachusetts, USA. Mithat received his M.A. degree in Chemistry from Queens College, City University of New York, USA. He has more than 20 years of research and preclinical development experience in drug metabolism and pharmacokinetics. Currently, he is a member of PK Sciences group within Novartis Institutes for Biomedical Research with the emphasis on metabolite identification, structure elucidation, and potential bioactivation of new chemical entities. Mithat has continued to be interested in Drug Metabolism and Pharmacokinetics, especially the area of bioactivation.
Dr. Qinghua Wu got the doctor's degree from Huazhong Agricultural University, China in 2013. During 2010-2011, Dr. Wu has studied as a visiting scholar in Institute of Food Chemistry, University of Muenster, Germany. Since 2014, he is an invited professor in University of Hradec Kralove. Since 2015.07, he began to be an associate professor in Yangtze University. His research interest is metabolism, pharmacokinetics, toxicokinetics, immunotoxicity, and food safety. Dr Wu has published more than 40 peer-reviewed articles in the field of metabolism and toxicology.
P. Anzenbacher Palacky University Olomouc Czech Republic
L. Berry USA
D. Brian Array Biopharma Boulder, CO USA
E. Chan National University of Singapore Singapore Singapore
K.-C. Cheng Schering-Plough Research Institute Kenilworth, NJ USA
M. Chetty University of Sydney Sydney Australia
B. Chowbay National Cancer Centre 11 Hospital Drive Singapore Singapore
C. Collins University of Washington Seattle, WA USA
M.T. Donato Universitat de València Valencia Spain
Z. Dvorak Palacky University Olomouc Moravia Czech Republic
A. El-Kadi University of Alberta Edmonton Canada
D. Fuchs Innsbruck Medical University Innsbruck Austria
A. Galetin University of Manchester Manchester UK
L.L. Gan Biogen Idec., Inc. Cambridge, MA USA
M. Gooyit USA
K. Grime AstraZeneca Research and Development Loughborough UK
J. Gu Jilin University Changchun China
C. Guo USA
Y. Guo USA
J. Hakkola University of Oulu Oulu Finland
N. Helsby University of Auckland Auckland New Zealand
N. Hewitt Scientific Writing Services Erzhausen Germany
P. Honkakoski University of Eastern Finland Kuopio Finland
B. Houston University of Manchester Manchester UK
M. Hu University of Houston Houston, TX USA
F. Innocenti University of Chicago Chicago, IL USA
H. Jeong University of Chicago Chicago, IL USA
Y. Jounaidi Boston University Boston, MA USA
A.S. Kalgutkar Pfizer Global Research and Development Groton, CT USA
R.A. Kemper Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, CT USA
G.M. Kirby University of Guelph Guelph, Ontario Canada
M. Kranendonk Universidade Nova de Lisboa Lisbon Portugal
J. Lambert The Pennsylvania State University University Park, PA USA
M. Liu USA
M.-C. Liu University of Toledo Toledo, OH USA
P.H. Marathe Bristol-Myers Squibb Princeton, NJ USA
F. Martel University of Porto Porto Portugal
H.H. Maurer Saarland University Homburg Germany
A. McLachlan University of Sydney and Concord Hospital Sydney Australia
R.P. Meyer University of Freiburg Freiburg Germany
B. Moorthy Baylor College of Medicine Houston, TX USA
A. Nishikawa National Institute of Health Sciences Tokyo Japan
A. Palotas Asklepios-Med Bt. Szeged Hungary
E. Schuetz St. Jude Children's Research Hospital Memphis, TN USA
M.-R. Shiran University of Medical Sciences Sari Iran
W. Tang Merck Research Laboratories Rahway, NJ USA
R. Tolando Celsis In Vitro Technologies Europadamm, Neuss Germany
Y.-F. Ueng Nat. Res. Inst.of Chinese Med. Taipei Taiwan
M. Vastag In vitro Metabolism Lab Budapest Hungary
K. Venkatakrishnan Millennium Pharmaceuticals Inc. Cambridge, MA USA
E.L. Woodahl University of Montana Missoula, MT USA
Z. Yan Johnson ' Johnson Pharmaceutical Research ' Development Spring House, PA USA
C.-H. Yun Chonnam National University Gwangju Republic of Korea
J.Y. Zhang China Novartis Institutes for Biomedical Research Co. Ltd. Shanghai China